Silicone Arts Labs Closes $1.5 Million Series A Round

Silicone Arts Laboratories, a medical product company and alum of the Health Wildcatters accelerator program, just announced the closing of their Series A Round with $1.5 Million, with Tennessee-based investor Innova as the round’s largest investor.

“The company’s traction and growth to date is very impressive, and we were especially attracted to the expanded market opportunities that will come from the continued innovation and product pipeline,” said Jan Bouten, Partner at Innova. “We are excited to be a part of their team.”

Silicone Arts Labs will use funding to grow its flagship product, Dermaflage. You might remember CEO Oscar Atkinson presenting on Dermaflage at our Holiday Dallas New Tech event.

Dermaflage is the first cosmetic synthetic skin and topical filler used to fill and conceal scars and wrinkles.

“We have assembled talent from the cosmetics arena and the medical device industry, and this capital infusion will allow us to expand the awareness level for our products,” said Silicone Arts Labs CEO Oscar Atkinson.

Silicone Arts Labs graduated from Health Wildcatters last year.

“We’re excited to watch Silicone Arts Labs grow,” said Dr. Hubert Zajicek, Health Wildcatters CEO. “With Dermaflage alone there’s a lot of potential. But considering the many practical applications of the technology, we expect to see a number of great products from them, both in the medical and cosmetic space.”

Additional investors in Silicone Arts Laboratories include Dallas-based Green Park & Golf Ventures. You can learn more about Silicone Arts Laboratories on their website. 

Rachel Winstead

Rachel is a freelance writer and works at Soap Hope in downtown Dallas. She hates the term "disrupt," tweets about startups, and appreciates a well-crafted hashtag.